AB076. High expression of FTL protein in prostate cancer and its clinical significance

BACKGROUND: To study the differential expression of FTL in prostate cancer and benign prostatic hyperplasia (BPH) and its clinical significance METHODS: Thirty cases of prostate cancer and 30 cases of BPH were selected according to the random number table method, and performed immunohistochemistry experiments; 4 cases of prostate cancer and 4 cases of BPH were collected, and performed protein blotting experiments. RESULTS: High expression rate of FTL protein in prostate cancer and BPH were 63.3% and 20%, respectively. The difference has statistically significant (P<0.05). The FTL protein was no significant difference in the groups of age, PSA, prostate volume, Gleason score, clinical stage and lymph node metastasis (P>0.05). The expression level of FTL protein has statistically significant in the group of distant metastases (P<0.05). The expression level of FTL protein in prostate cancer and BPH were (1.52±0.27) and (0.41±0.21), respectively, and it has statistically significant (P<0.05). CONCLUSIONS: FTL protein is highly expressed in prostate cancer, and it can be used as a new diagnostic tool for prostate cancer. FTL protein plays an important role in the development of prostate cancer.